newsfilter
← Latest News
GlobeNewswire·

Icosavax Reports Second Quarter 2023 Financial Results and Provides Corporate Update

- Positive topline interim Phase 1 results for bivalent VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults - - Positive twelve-month immunogenicity data and initial proof-of-concept for revaccination